Eradicating the seed of cancer drug resistance

TOLREMO therapeutics AG aims to fundamentally change the way modern cancer drugs are used. The company’s resistance-breaking add-on therapies boost the long-term efficacy of existing cancer drugs by inhibiting nongenetic mechanisms of cancer drug resistance.

Go to the profile of TOLREMO therapeutics
Mar 12, 2019
0
0
Page of
Go to the profile of TOLREMO therapeutics

TOLREMO therapeutics

TOLREMO therapeutics AG (“TOLREMO”) was founded on ground-breaking scientific discoveries in the field of drug resistance in cancer. TOLREMO's proprietary drug discovery and development platform has the potential to catalyze a new wave of novel resistance-breaking therapies that will meaningfully extend the lives of patients suffering from cancer.

No comments yet.